KR101791715B1 - 라사길린의 연장 방출 제형 및 그 용도 - Google Patents

라사길린의 연장 방출 제형 및 그 용도 Download PDF

Info

Publication number
KR101791715B1
KR101791715B1 KR1020127023006A KR20127023006A KR101791715B1 KR 101791715 B1 KR101791715 B1 KR 101791715B1 KR 1020127023006 A KR1020127023006 A KR 1020127023006A KR 20127023006 A KR20127023006 A KR 20127023006A KR 101791715 B1 KR101791715 B1 KR 101791715B1
Authority
KR
South Korea
Prior art keywords
polymer
total
layer
weight
rasagiline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020127023006A
Other languages
English (en)
Korean (ko)
Other versions
KR20120130292A (ko
Inventor
요람 세라
뉴라이트 리브나흐
잇츠차크 라멘스도르프
토머 마드몬
Original Assignee
파마 투 비 엘티디
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43896855&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101791715(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 파마 투 비 엘티디 filed Critical 파마 투 비 엘티디
Publication of KR20120130292A publication Critical patent/KR20120130292A/ko
Application granted granted Critical
Publication of KR101791715B1 publication Critical patent/KR101791715B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020127023006A 2010-02-03 2011-02-03 라사길린의 연장 방출 제형 및 그 용도 Active KR101791715B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30101910P 2010-02-03 2010-02-03
US61/301,019 2010-02-03
PCT/IL2011/000126 WO2011095973A1 (en) 2010-02-03 2011-02-03 Extended release formulations of rasagiline and uses thereof

Publications (2)

Publication Number Publication Date
KR20120130292A KR20120130292A (ko) 2012-11-30
KR101791715B1 true KR101791715B1 (ko) 2017-10-30

Family

ID=43896855

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127023006A Active KR101791715B1 (ko) 2010-02-03 2011-02-03 라사길린의 연장 방출 제형 및 그 용도

Country Status (25)

Country Link
US (1) US9943489B2 (cg-RX-API-DMAC7.html)
EP (2) EP3517103A1 (cg-RX-API-DMAC7.html)
JP (3) JP6045347B2 (cg-RX-API-DMAC7.html)
KR (1) KR101791715B1 (cg-RX-API-DMAC7.html)
CN (1) CN102791258B (cg-RX-API-DMAC7.html)
AU (1) AU2011212068B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012019374B1 (cg-RX-API-DMAC7.html)
CA (1) CA2789006C (cg-RX-API-DMAC7.html)
CL (1) CL2012002175A1 (cg-RX-API-DMAC7.html)
CY (1) CY1121781T1 (cg-RX-API-DMAC7.html)
DK (1) DK2531181T3 (cg-RX-API-DMAC7.html)
ES (1) ES2733133T3 (cg-RX-API-DMAC7.html)
HU (1) HUE044221T2 (cg-RX-API-DMAC7.html)
IL (1) IL221274A (cg-RX-API-DMAC7.html)
LT (1) LT2531181T (cg-RX-API-DMAC7.html)
MX (1) MX354423B (cg-RX-API-DMAC7.html)
NZ (1) NZ602111A (cg-RX-API-DMAC7.html)
PL (1) PL2531181T3 (cg-RX-API-DMAC7.html)
PT (1) PT2531181T (cg-RX-API-DMAC7.html)
RS (1) RS58988B1 (cg-RX-API-DMAC7.html)
RU (2) RU2607595C2 (cg-RX-API-DMAC7.html)
SG (1) SG183150A1 (cg-RX-API-DMAC7.html)
TR (1) TR201909277T4 (cg-RX-API-DMAC7.html)
WO (1) WO2011095973A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201206462B (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2607595C2 (ru) * 2010-02-03 2017-01-10 Фарма Ту Б Лтд. Составы разагилина с пролонгированным высвобождением и их применение
CA2758556A1 (en) * 2011-11-17 2013-05-17 Pharmascience Inc. Pharmaceutical composition of amphetamine mixed salts
WO2013105092A1 (en) * 2012-01-12 2013-07-18 Pharma Two B Ltd. Fixed dose combination therapy of parkinson's disease
US9504657B2 (en) * 2012-01-12 2016-11-29 Pharmatwob Ltd. Fixed dose combination therapy of Parkinson's disease
CN102579367B (zh) * 2012-03-23 2014-03-12 中国人民解放军军事医学科学院毒物药物研究所 托吡酯缓释药物组合物、其制备方法及用途
CN103316026B (zh) 2012-03-23 2016-05-11 中国人民解放军军事医学科学院毒物药物研究所 含芬特明和托吡酯的联合产品及其制备方法
EP2829270B1 (en) 2012-03-23 2020-11-11 Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China Joint product containing synephrine and topiramate
US9308182B2 (en) 2012-08-17 2016-04-12 Teva Pharmaceutical Industries, Ltd. Parenteral formulations of rasagiline
IN2013MU01782A (cg-RX-API-DMAC7.html) * 2013-05-20 2015-06-26 Cadila Healthcare Ltd
US20150275167A1 (en) * 2014-03-28 2015-10-01 Corning Incorporated Composition and method for cell culture sustained release
US10709700B2 (en) * 2014-09-15 2020-07-14 Orphazyme A/S Arimoclomol formulation
WO2018213838A1 (en) * 2017-05-19 2018-11-22 Biscayne Neurotherapeutics, Inc. Modified release pharmaceutical compositions of huperzine and methods of using the same
CN107049985B (zh) * 2017-06-07 2020-06-19 广州帝奇医药技术有限公司 一种抗帕金森病药物的长效缓释制剂及其制备方法
CN112384210A (zh) * 2018-04-25 2021-02-19 纽罗森特里亚股份有限公司 苏糖酸镁组合物及其用途
MX2021004586A (es) 2018-11-19 2021-06-15 Supernus Pharmaceuticals Inc Uso de dosis mas altas de formulaciones de huperzina de liberacion modificada.
JP7714473B2 (ja) * 2019-05-31 2025-07-29 デナリ セラピューティクス インコーポレイテッド ピリミジニルアミノピラゾール化合物の調節放出製剤および処置方法
KR20210014289A (ko) 2019-07-30 2021-02-09 (주)비씨월드제약 라사길린을 함유하는 서방출성 미립구의 제조방법
AR121619A1 (es) * 2020-03-25 2022-06-22 Inibsa Ginecologia S A Una forma de dosificación oral de múltiples unidades de liberación modificada de succinato de doxilamina y clorhidrato de piridoxina y un procedimiento para su preparación
WO2022238401A1 (en) * 2021-05-11 2022-11-17 Advicenne Prolonged-release pharmaceutical composition for oral administration of sultiame
CN117355296A (zh) * 2021-05-11 2024-01-05 阿德维斯尼公司 用于口服施用舒噻美的延长释放药物组合物
CN118680910B (zh) * 2024-08-26 2024-12-03 山东齐都药业有限公司 用于缓释递送雷沙吉兰甲磺酸盐的药物组合物及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006502108A (ja) 2002-07-03 2006-01-19 ファイザー・プロダクツ・インク 徐放性医薬製剤
US20060018957A1 (en) 2004-07-26 2006-01-26 Lerner E I Pharmaceutical dosage forms including rasagiline

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4415547A (en) * 1982-06-14 1983-11-15 Sterling Drug Inc. Sustained-release pharmaceutical tablet and process for preparation thereof
US4861800A (en) 1987-08-18 1989-08-29 Buyske Donald A Method for administering the drug deprenyl so as to minimize the danger of side effects
HU208484B (en) 1988-08-17 1993-11-29 Chinoin Gyogyszer Es Vegyeszet Process for producing pharmaceutical composition containing acid additional salt of selegilin as active component for treating schisofrenia
US5744500A (en) 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL92952A (en) * 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
US5192808A (en) 1990-08-31 1993-03-09 Deprenyl Animal Health, Inc. Therapeutic effect of L-deprenyl in the management of pituitary-dependent hyperadrenocorticism (cushing's disease)
US5151449A (en) 1990-08-31 1992-09-29 Deprenyl Animal Health, Inc. Use of L-deprenyl for retention of specific physiological functions
CA2039194C (en) 1990-08-31 1997-01-28 Norton W. Milgram Uses of l-deprenyl and compositions for same
US5225446A (en) 1990-08-31 1993-07-06 Deprenyl Animal Health, Inc. Use of 1-deprenyl for retention of specific physiological functions
US5169868A (en) 1991-03-01 1992-12-08 University Of Saskatchewan Aliphatic propargylamines as specific mao-b inhibitors
EP1413299A3 (en) 1991-04-04 2004-05-06 The University Of Toronto Innovations Foundation Use of deprenyl analogues to maintain, prevent loss, or recover nerve cell function
AU1992592A (en) 1991-05-24 1993-01-08 Pharmavene, Inc. Treatment of drug withdrawal symptoms and drug craving with type b monoamine oxidase inhibitors
IL99759A (en) 1991-10-16 1997-06-10 Teva Pharma Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them
US5242950A (en) 1992-04-23 1993-09-07 Somerset Pharmaceuticals, Inc. Treatment of macular degeneration
JP2916978B2 (ja) * 1993-08-25 1999-07-05 エスエス製薬株式会社 放出開始制御型製剤
IL111240A (en) * 1993-10-18 2001-10-31 Teva Pharma Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
US6348208B1 (en) 1995-01-13 2002-02-19 Somerset Pharmaceuticals, Inc. Methods and pharmaceutical compositions employing desmethylselegiline
PE57198A1 (es) * 1996-03-25 1998-10-10 American Home Prod Formula de liberacion prolongada
IL118836A (en) 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
DE69738275T2 (de) 1996-12-18 2008-08-28 Teva Pharmaceutical Industries Ltd. Aminoindanderivate
US6251938B1 (en) 1996-12-18 2001-06-26 Teva Pharmaceutical Industries, Ltd., Phenylethylamine derivatives
US5840979A (en) 1997-07-14 1998-11-24 University Of Saskatchewan Aliphatic propargylamines as cellular rescue agents
EP1185259A1 (en) 1999-04-29 2002-03-13 MERCK PATENT GmbH Glycine cleavage system inhibitors as potential antipsychotics
RU2325152C2 (ru) * 2001-07-04 2008-05-27 Сан Фармасьютикл Индастриз Лимитид Удерживаемая в желудке система регулируемой доставки лекарственного средства
SI1567152T1 (sl) * 2002-11-15 2013-10-30 Teva Pharmaceutical Industries Ltd. Uporaba rasagilina z riluzolom za zdravljenje amiotrofične lateralne skleroze
EP1715843A1 (en) * 2004-01-29 2006-11-02 Neuromolecular Inc. Combination of a nmda receptor antagonist and a mao-inhibitor or a gadph-inhibitor for the treatment of central nervous system-related conditions
US20090099154A1 (en) * 2005-06-29 2009-04-16 Panacea Biotec Ltd. Pharmaceutical Sustained Release Compositions and Processes Thereof
JP2009502957A (ja) * 2005-07-28 2009-01-29 スパーナス ファーマシューティカルズ インコーポレイテッド 機械的特性の向上した徐放性錠剤配合物
US20070048371A1 (en) * 2005-07-28 2007-03-01 Shojaei Amir H Pharmaceutical formulations/composition of guanfacine suitable for single dose form administration daily
CN101032474B (zh) * 2006-03-06 2011-02-16 重庆医药工业研究院有限责任公司 一种治疗或预防神经系统疾病的雷沙吉兰透皮贴片及其制备方法
CN101486655A (zh) * 2008-01-17 2009-07-22 美德（江西）生物科技有限公司 甲磺酸雷沙吉兰晶形及其制备方法
US8969417B2 (en) 2008-06-06 2015-03-03 Pharmatwob Ltd. Pharmaceutical compositions for treatment of Parkinsons disease
WO2009151594A1 (en) * 2008-06-10 2009-12-17 Teva Pharmaceutical Industries, Ltd. Rasagiline soft gelatin capsules
WO2010007181A2 (en) * 2008-07-18 2010-01-21 Medichem, S.A. New salt forms of an aminoindan derivative
EP2218444A3 (en) * 2009-01-23 2010-08-25 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline formulation
RU2607595C2 (ru) * 2010-02-03 2017-01-10 Фарма Ту Б Лтд. Составы разагилина с пролонгированным высвобождением и их применение

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006502108A (ja) 2002-07-03 2006-01-19 ファイザー・プロダクツ・インク 徐放性医薬製剤
US20060018957A1 (en) 2004-07-26 2006-01-26 Lerner E I Pharmaceutical dosage forms including rasagiline

Also Published As

Publication number Publication date
JP2017031189A (ja) 2017-02-09
CL2012002175A1 (es) 2013-01-11
CN102791258B (zh) 2018-05-08
JP6440662B2 (ja) 2018-12-19
TR201909277T4 (tr) 2019-07-22
RU2016141314A (ru) 2018-12-14
PT2531181T (pt) 2019-07-17
RU2016141314A3 (cg-RX-API-DMAC7.html) 2019-12-20
EP2531181B1 (en) 2019-04-10
DK2531181T3 (da) 2019-07-15
RU2607595C2 (ru) 2017-01-10
HUE044221T2 (hu) 2019-10-28
JP6770564B2 (ja) 2020-10-14
BR112012019374B1 (pt) 2022-01-11
RU2734632C2 (ru) 2020-10-21
EP2531181A1 (en) 2012-12-12
RU2012136723A (ru) 2014-03-10
US9943489B2 (en) 2018-04-17
JP2019048855A (ja) 2019-03-28
MX2012009079A (es) 2012-12-17
SG183150A1 (en) 2012-09-27
LT2531181T (lt) 2019-07-10
KR20120130292A (ko) 2012-11-30
EP3517103A1 (en) 2019-07-31
WO2011095973A1 (en) 2011-08-11
CN102791258A (zh) 2012-11-21
US20120301542A1 (en) 2012-11-29
IL221274A (en) 2017-05-29
RS58988B1 (sr) 2019-08-30
ES2733133T3 (es) 2019-11-27
JP6045347B2 (ja) 2016-12-14
PL2531181T3 (pl) 2019-09-30
IL221274A0 (en) 2012-10-31
BR112012019374A2 (pt) 2016-05-03
JP2013518870A (ja) 2013-05-23
CY1121781T1 (el) 2020-07-31
NZ602111A (en) 2014-10-31
ZA201206462B (en) 2014-02-26
AU2011212068B2 (en) 2016-08-18
CA2789006C (en) 2018-11-27
CA2789006A1 (en) 2011-08-11
AU2011212068A1 (en) 2012-09-20
MX354423B (es) 2018-03-02

Similar Documents

Publication Publication Date Title
KR101791715B1 (ko) 라사길린의 연장 방출 제형 및 그 용도
US20060257482A1 (en) Modified release, multiple unit drug delivery systems
JP2005506367A (ja) 有効物質を徐放する３−（３−ジメチルアミノ−１−エチル−２−メチル−プロピル）フェノール含有医薬
CA2860952C (en) Fixed dose combination therapy of parkinson's disease
US9504657B2 (en) Fixed dose combination therapy of Parkinson's disease
US20140112995A1 (en) Multi-layered, multiple unit pharmaceutical compositions
RU2771522C9 (ru) Терапия болезни паркинсона с применением комбинации с фиксированными дозами
CA3226799A1 (en) Multiparticulate pharmaceutical composition
EP2886110A1 (en) Multi-layered, multiple unit pharmaceutical compositions
HK1203847B (en) Fixed dose combination therapy of parkinson's disease
EP1545473A2 (en) Modified release, multiple unit drug delivery systems

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20120903

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20160202

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20170109

Patent event code: PE09021S01D

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20170802

Patent event code: PE09021S02D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20170913

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20171024

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20171024

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20201016

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20201016

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20211015

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20211015

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20221013

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20221013

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20231012

Start annual number: 7

End annual number: 7